OXBRYTA is indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial. OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial.